首页> 美国卫生研究院文献>other >Hydrophilic Polymer Embolism: Implications for Manufacturing Regulation and Postmarket Surveillance of Coated Intravascular Medical Devices
【2h】

Hydrophilic Polymer Embolism: Implications for Manufacturing Regulation and Postmarket Surveillance of Coated Intravascular Medical Devices

机译:亲水性聚合物栓塞:对涂层内血管内医疗器械的制造监管和上市后监视的意义

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Hydrophilic polymers are ubiquitously applied as surface coatings on catheters and intravascular medical technologies. Recent clinical literature has heightened awareness on the complication of hydrophilic polymer embolism (HPE), the phenomenon wherein polymer coating layers separate from catheter and device surfaces, and may be affiliated with a range of unanticipated adverse reactions. Significant system barriers have limited and delayed reporting on this iatrogenic complication, the full effects of which remain under-recognized by healthcare providers and manufacturers of various branded devices. In 2015, the United States Food and Drug Administration acknowledged rising clinical concerns and stated that the agency would work with stakeholders to further evaluate gaps that exist in current national and international device standards for coated intravascular medical technologies. The present article reviews current knowledge on this complication as well as factors that played a role in delaying detection and dissemination of information and new knowledge once hazards and clinical risks were identified. Furthermore, organ-specific effects and adverse reaction patterns are summarized, along with implications for device manufacturing, safety testing, and regulation. Particulate analyses and general enhanced processes for device surveillance are needed to optimize vascular technologies and to ensure patient safety.
机译:亲水性聚合物作为导管和血管内医疗技术的表面涂层无处不在。最近的临床文献已经提高了对亲水性聚合物栓塞(HPE)并发症的认识,该现象是聚合物涂层与导管和器械表面分离的现象,并且可能与一系列意想不到的不良反应有关。严重的系统障碍限制了这种医源性并发症的报道,并延迟了报告的时间,其全部效果仍未得到医疗保健提供商和各种品牌设备制造商的充分认识。 2015年,美国食品和药物管理局(FDA)意识到临床关注的上升,并表示该机构将与利益相关方合作,进一步评估目前国家和国际涂层血管内医疗技术设备标准中存在的差距。本文回顾了有关此并发症的当前知识,以及一旦确定了危害和临床风险,在延迟信息和新知识的发现和传播中起作用的因素。此外,还总结了器官特异性作用和不良反应模式,以及对器件制造,安全性测试和法规的影响。需要颗粒分析和设备监控的一般增强过程来优化血管技术并确保患者安全。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号